





Please type a plus sign (+) inside this box

SEP 05 2001

1

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

<i>Complete if Known</i>	
Application Number	09/402,634
Filing Date	March 27, 2001
First Named Inventor	Barbara Roniker et al.
Group Art Unit	1614
Examiner Name	D. Jagoe
Attorney Docket Number	51765.00002

RECEIVED

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>MR</i>	1.	P.M. Ridker et al., <i>"Inflammation, A Spin and the Risk of Cardiovascular Disease in Apparently Healthy Men,"</i> The New England Journal of Medicine, Vol. 336, No. 14, pp. 973-979, April 3, 1997	
<i>J</i>	2.	Dialog Abstract 009568042 for JP 05-178745 (Toyama Chem. Co. Ltd.) 1993.	
<i>YJ</i>	3.	Dialog Abstract 009068747 for JP-04-124130 (Fujisawa Pharm. Co. Ltd.) 1992.	

Examiner Signature		Date Considered	11/3/10
--------------------	---	-----------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.